Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 36 Cholangiocarcinoma 11 Carcinoma, Renal Cell 10 Stomach Neoplasms 5 Liver Neoplasms 5 Neoplasms 4 Endometrial Neoplasms 4 Biliary Tract Neoplasms 4 Uterine Cervical Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Vulvar Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Liver Diseases 2 Kidney Neoplasms 2 Cirrhosis, Familial, with Pulmonary Hypertension 2 Breast Neoplasms 2 Advanced Solid Tumor 2 von Hippel-Lindau Disease 1 Urogenital Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumor, Adult 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Penile Neoplasms 1

Interventions

Cyclophosphamide 22 fludarabine 20 venetoclax 8 Whole-Body Irradiation 8 Mycophenolic Acid 8 Standard of Care 6 Mesna 6 Melphalan 6 Azacitidine 6 fludarabine phosphate 5 Sirolimus 5 thymoglobulin 4 Thiotepa 4 Tacrolimus 4 Specimen Handling 4 Filgrastim 4 Cytarabine 4 entrectinib 3 daratumumab 3 cobimetinib 3 alectinib 3 Vemurafenib 3 Surveys and Questionnaires 3 Rituximab 3 Practice Guidelines as Topic 3 Palliative Care 3 Granulocyte Colony-Stimulating Factor 3 Busulfan 3 Bortezomib 3 Blood Specimen Collection 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Hematologic Neoplasms × lenvatinib × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡